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Abstract
Background: Scientific information on the number of IPT beneficiaries, their rate of adherence vis-
à-vis determinants of adherence is scarce in Ethiopia. Hence, it was practically impossible to discuss
whether the preventive therapy was reaching those who were in need of the service or whether it was
being rationally used.
Objective: The main objective of the study was to assess the implementation of IPT, adherence to
the treatment and its determinants.
Methods: This cross-sectional study was conducted in five ART service providing public health
facilities of Dire Dawa City Administration from April to May, 2009. Primary data was collected
through patient exit interviews of 238 PLHIV who were on IPT and in-depth interview of 4 health
service managers, while secondary data was collected from health facilities through observation.
SPSS V.16 was used for data anlysis. Descriptive statistics was generated for socio-demographic and
other quantitative data while thematic analysis was conducted for qualitative data. Binary logistic
regression tests were performed to analyze the degree of association between the dependent and the
independent variables. Odds ratio was determined using cross-tabulation on respondents’ age and sex
to analyze association with adherence level.
Results: In general, health facilities’ organizational capacity was assessed to be good whereas there
were observed differences among the facilities in patient load and service availability. However, IPT
service coverage  and adherence level were generally low in the studied health facilities with only
179 (37.3%) individuals receiving INH among the eligible 480 with aggregated treatment adherence
level of respondents being 84.8% and self-reported full adherence level being 78.2%. Being away
from home, forgetfulness and running out of pills were identified as the major reasons for missing
INH doses, which implies that the most important factors for adherence were usually those that are
related to the patients themselves; and contributions of health service and community level factors to
non-adherence were minimal. Socio-demographic and patient care variables were not found to have
significant association with the level of adherence.
Conclusion and recommendations: Attitude and follow-up were found to be the main challenges
for better service utilization and appropriate adherence. Therefore, improving attitude, strengthening
service provision follow up, designing and implementing appropriate strategies that strengthen
adherence counseling and patients follow up are recommended.
11. Introduction
1.1. Background
The Human Immunodeficiency Virus (HIV) pandemic brought about a great challenge to the TB
prevention and control Program. It has been found that latent TB infection in HIV-positive
individuals reactivates at a rate of 10% per year as opposed to 5%-10% over a life time risk for
HIV-negative individuals (1). According to the World Health Organization (WHO), out of the
total of 9.3 million incident cases of TB, there were 1.4 million new HIV-positive TB cases in
2007. The African Region accounts for 79% of estimated HIV-positive TB cases; most of the
remaining cases are in South-East Asia Region (2).
To reduce the burden of TB in HIV infected individuals, TB preventive therapy was first
recommended by WHO and UNAIDS in 1998 along with other key interventions. Preventive
therapy for TB is safe and efficacious and is recommended for all PLHIV living in areas with a
prevalence of latent TB infection >30%, and for all PLHIV with documented latent TB infection
or exposure to an infectious TB case, regardless of where they live. Subsequently, in 2004, WHO
incorporated the Isoniazid preventive therapy (IPT) as one of the twelve key TB/HIV
collaborative activities to reduce the huge impact of the co-infection (3). The requirements for
the implementation of preventive therapy included adequate HIV counseling, sufficient trained
health-care providers, linkage of HIV-care and TB-control services, and TB treatment services
that have a high probability of curing cases of TB (4).
2Many national TB and HIV programs, however, had chosen not to implement the policy. HIV
care programs had instead focused efforts on the logistics of scaling up the life saving
intervention of antiretroviral therapy (ART) at the expense of implementing other interventions
such as preventive therapy. Other concerns about preventive therapy had also contributed to its
low uptake, including difficulties in ruling out active TB before starting, the risk of producing
INH-resistant TB, and toxicity of INH, especially in combination with antiretrovirals (ARVs).
As a result, only 0.06% of PLHIV worldwide were given TB preventive therapy in 2005 (5). In
2007, the proportion of estimated number of HIV-positive people who received IPT among the
eligible ones increased to 0.2% globally and 0.1% for Africa (2).
The other issue associated with IPT was the high rate of defaulters observed in different
countries; some studies revealed that the defaulter rate could go as high as 37% (6). Despite the
fact that compliance is one of the factors that determines the success of the preventive therapy,
studies conducted in different places documented poor adherence. For instance a study in South
Africa reported 28% non-adherence while in America it was reported to be 17.8% (7,8). Another
study in Thailand documented 32.5% non-adherence rate for IPT among HIV infected
individuals in Chiang Rai province (9).
Like the rest of the world, the HIV pandemic presented a massive challenge to the control of
tuberculosis (TB) in Ethiopia. Routine data collected from health facilities indicated 41% and
31% co-infection rates in the years 2005/6 and 2006/7, respectively (1). For 2007, WHO
estimated that 19% of new TB cases in Ethiopia were HIV-positive (2). Besides the synergistic
health consequences, the dual infections have a number of impacts on the health system that
3resulted from huge demand for health services. Cognizant of this fact, the national TB and HIV
prevention and control programs designed and implemented a collaborative strategy in May 2004
that aimed at prevention of HIV and prevention and control of TB, which ultimately would
reduce the burden of both infections (10). The collaborative work was initiated as a pilot project
in six hospitals and three health centers to expand to more than 330 health facilities by 2008
(11).The national TB/HIV collaboration adopted the twelve, WHO recommended collaborative
activities of which Isoniazid Preventive Therapy (IPT) was one.
1.2. Rationale
IPT was incorporated as one of the activities in the national Implementation guidelines for
TB/HIV collaborative activities in Ethiopia only in 2008. But, there were many reasons to
believe that it had been implemented at some health facilities of the country since 2005. So far,
there are no studies in the country that assessed the implementation of IPT and the rate of
adherence to the therapy. Moreover, reasons for non-compliance and the possible determinants
of adherence have not been studied in Ethiopia. Though it is difficult to get a complete report,
however, the number of individuals who benefited from IPT was reported to be low throughout
the nation. This makes it practically impossible to discuss whether the preventive therapy had
reached those who were in need of the service or whether INH was being rationally used.
This information gap made it impossible to plan and implement appropriate interventions with
regards to expanding the service and improving adherence. This study is, therefore, aimed at
providing information that would help for future programmatic decisions with regards to
expanding the use of IPT and improving adherence.
42. Literature review
2.1. Global and national TB/HIV burden
HIV is the primary reason for failure to meet tuberculosis (TB) control targets in settings with a
high prevalence of HIV infection. Although sub-Saharan Africa bears the brunt of the HIV-
fuelled TB epidemic, TB is a major cause of death among people living with HIV/AIDS
worldwide (12). If one looks at the HIV prevalence among new TB cases globally, 1.37 million
(14.8%) of 9.27 million incident cases of TB in 2007 were HIV positive. Of these co-infection
cases, the African Region accounted for 79 % followed by South-East Asia Region with 11% of
cases. For Ethiopia, the reported figure was 19% for the same year (2).
2.2. Impacts of TB/HIV
The synergy between TB and HIV/AIDS is strong: TB is a leading cause of morbidity and
mortality, and HIV is driving the tuberculosis epidemic in many countries. HIV increases
susceptibility to infection with Mycobacterium tuberculosis, the risk of progression to TB
disease, and the likelihood of re-infections and relapses (1). On the other hand, TB is often the
first and most common opportunistic infection in HIV infected individuals resulting in disease
progression and mortality. For instance, WHO estimates that 230,000 people living with HIV
would have died as a result of TB in 2008 only; this is around 630 persons per day despite the
fact that TB is curable and possibly preventable (13).
52.3. TB/HIV collaboration
In 2004, WHO issued a policy on TB/HIV Collaborative Activities to accelerate implementation
of the twelve recommended activities that reduce the TB and HIV co-epidemic. These
recommendations were categorized under three major objectives: establishment of mechanisms
for collaboration between TB and HIV control programs, reducing the burden of TB in people
living with HIV and reducing the burden of HIV in people infected with TB (5). The so called
Three I’s strategy was selected by WHO and collaborative partners to achieve the second goal,
which aimed at reducing the burden of TB in PLHIV. The Three I’s are: intensified case finding
(ICF), Isoniazid preventive therapy (IPT) and TB infection control (IC) (13).
Although global consensus had been achieved around an interim policy on TB/HIV, the wide
dissemination of the policy was not satisfactory, and implementation of joint TB/HIV activities
had not been scaled up till 2005 (12). In 2006, however, the number of countries implementing
collaborative TB/HIV activities and related services significantly increased to 112, from just 7
countries in 2003 (14). Ethiopia has been part of this global effort since 2004, when the national
TB/HIV collaborative activities strategy was developed and implemented.
2.4. Isoniazid preventive therapy
Preventive therapy (PT) against TB is the use of one or more anti-TB drugs given to individuals
with latent Mycobacterium tuberculosis infection in order to prevent the progression to active
disease. HIV is known to be the most powerful risk factor for progression from latent infection to
active disease. While non-immunocompromised persons with latent infection have about 5%
chance of developing active TB later in life, the chance rises to 50% in HIV-infected individuals.
6In high TB prevalence countries, between 2.4% to 7.5% of HIV-infected adults may develop
active TB each year (6).
The efficacy of PT in the prevention of the progression to active TB in HIV-infected persons is
supported by a number of researches. In one randomized clinical trial, it was reported that IPT
reduces the risk of developing active TB significantly with additional advantage of delaying
disease progression and death in HIV-infected individuals (15). One other study in Thailand
documented that randomized trials administering Isoniazid for 6 months and 12 months duration
have shown a significant decrease of TB incidence in tuberculin skin test positive persons
compared to those who took placebo. IPT for tuberculin skin test positive persons living in areas
with high TB prevalence will reduce the risk of developing active TB in short term to around
40% of what it would have been without such treatment (6). In one other review, 11 trials were
included with a total of 8,130 randomized participants and preventive therapy (any anti-TB drug)
versus placebo was associated with a lower incidence of active tuberculosis (RR 0.64, 95% CI
0.51 to 0.81) (16). In one WHO document, it was stated that a meta-analysis showed an overall
efficacy of 64% in tuberculin positive individuals while in populations from high burden areas
with a mix of tuberculin-positive and negative individuals the overall efficacy was 33%. A
morbidity and mortality weekly report of CDC documented that IPT has 95% efficacy among
infected individuals who have completed the treatment (17).
Isoniazid preventive therapy has not been extensively studied in HIV-infected children. In one
placebo-controlled randomized trial, INH dosed at 10 mg/kg orally once daily or three times
weekly was associated with a 53 percent reduction in mortality. The survival benefit occurred
early (within 50 days) and was apparent in all CDC HIV categories of disease. Although the
7results were preliminary and the population studied lived in the Western Cape Province of South
Africa, a region with one of the highest incidence rates of TB worldwide (4.1 percent annualized
risk for children), they made a strong case for offering Isoniazid preventive therapy to HIV
infected children living in other countries with high TB prevalence (18).In another small,
randomized trial, INH preventive therapy was shown to reduce early mortality by 50% in
children living with HIV (19).
With regards to efficacy of secondary prophylaxis, treatment of latent TB in those who have
already been treated for active TB, a study in South Africa reported a 55% reduction in the
incidence of recurrent TB among men who received IPT compared with those who did not (7).
However, a recent WHO document indicated that secondary preventive therapy was not
recommended, though several trials and cohort studies suggested possible benefit (19).
In summary, many literatures indicate that TB preventive therapy is safe and effective in PLHIV,
reducing the risk of TB significantly. As per WHO guidelines, IPT is efficacious and is
recommended for all people living with HIV in countries where tuberculosis is common and in
all those with documented co-infection, regardless of where they live. The recommended dose of
INH for TB preventive therapy in adolescents and adults living with HIV is 300 mg daily for
nine months, with six months being an acceptable alternative. Isoniazid 800-900 mg twice
weekly is an effective and well tolerated alternative regimen that can be offered where treatment
supervision is feasible. For children, Isoniazid 5 mg/kg for nine months is the recommended
regimen (20).
82.5. Issues in INH Preventive Therapy
Despite the strong recommendation by WHO, implementation of IPT had been reported to be
very low in a number of documents (10, 19). Only 25,000 (0.06%) people living with HIV
worldwide were reported to have received it in 2005. In 2007, only 29 countries had policies
related to IPT (2). Though securing sufficient amount of fund for effective implementation of
IPT was forwarded as the main reason of failure, it is evident that reluctance to its
implementation is driven primarily for technical and logistical difficulties of excluding active TB
and fear of development of drug resistance. However, except one review of literatures that
indicated an increased risk for INH-resistant TB (21), many of the documents reviewed did not
provide any evidence of resistance development due to IPT.
Adherence to INH preventive therapy is an important issue, and interventions to promote
adherence may be very useful (19). A controlled trial cited Healthy People 2010 for calling for
90% of LTBI patients to complete treatment (22). However, the same study reported an observed
treatment completion rate as low as 5% among adults and 50% among adolescents. A feasibility
studies on 9 months daily self-administered INH in one regional hospital in Thailand established
that the process of targeting appropriate groups (e.g. excluding active TB), delivering preventive
therapy and achieving adherence, was complex. In addition, data collected from 26 hospitals in
the Northern part of Thailand found out that the defaulter rate was as high as 37%. The study
also showed that defaulter rate increased over time. The possible determinants the study
identified for low level of adherence were weak service integration and inadequate pre and post
treatment counseling (6).
9In all the literatures reviewed, there was no agreed figure mentioned as an acceptable level of
adherence to IPT. A review of adherence studies for chronic illnesses found that achieving
adherence rates above 80 percent is difficult, even in resource-rich countries (23). Various
incentives and enablers have been known to improve adherence in diverse populations of people
receiving IPT (19). Based on the findings from different literatures and taking the local situation
and context in to consideration, a simple conceptual framework was developed to help
understand the relationship of the different factors with adherence (Figure 1). However, the fact
is that the interactions might be more complex than described below.
Figure 1 Conceptual framework relating adherence to IPT with different factors
Health Service factors:
 Accessibility to patients
 Work load
 Patient-provider
interaction
 Supply of drugs
 Laboratory service
 Waiting time
 Integration of services
 Follow up
Adherence to IPT
Individual factors:
 Side effect/toxicity
 Information on
treatment
 Self discipline
 Acceptance and denial
of status and treatment
 Financial resource
 Other drugs
 Disease status
 Religious factors
Community level factors:
 Perception about disease
and treatment
 Community support
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In Ethiopia, IPT has been incorporated in the 2008 national ‘Implementation Guidelines for
TB/HIV Collaborative Activities in Ethiopia’ and is being implemented throughout the country.
But, at central level, it was difficult to get a comprehensive report on the IPT service utilization
coverage. During the literature review, no documented study was found that measured the
prevalence of IPT and adherence in Ethiopia. Yet, in the national guideline, five practical
barriers to IPT use were pointed out: fear of resistance development, fear of side effect, fear of
re-infection, attitude and follow-up. Some other operational factors such as organization of the
services and availability of drugs were not indicated as possible challenges.
In general, there is a huge information gap with regards to IPT implementation in the country.
Macro level and individual factors that affect IPT use and adherence were not documented.
11
3. Objectives
3.1. General objective:
 The main objective of the study was to assess the implementation of Isoniazid Preventive
Therapy (IPT), adherence to the treatment and its determinants in the public health facilities of
Dire Dawa City Administration.
.
3.2. Specific objectives:
 To assess health facilities organizational capacity in terms of IPT service provision;
 To determine the prevalence of IPT among eligible PLHIV;
 To measure the degree of adherence to IPT;
 To identify reasons for non-adherence and factors that affect adherence to IPT.
12
4. Study methodology
4.1. Study area
The study was conducted in Dire Dawa city administration, which is located 520 Km away from
the capital Addis Ababa in the Eastern part of the country with an estimated population size of
371,000. Administratively, Dire Dawa is divided in to 9 urban kebeles and 32 peasant
associations. The city administration has a total of 50 public health facilities comprised of one
hospital, 12 health centers and 37 health posts. Currently, there are six health facilities in Dire
Dawa that are providing ART service including one private hospital. According to the
FHAPCO’s Tahisas, 2001 E.C. (December, 2008) report, the ever enrolled number of HIV-
positive individuals was 5466 for Dire Dawa.
Dire Dawa was purposely selected for the reason that there were evidences of better IPT service
coverage in Dire Dawa as compared to other parts of the country, satisfying the necessary
condition for adherence assessment. Accordingly, all the five public facilities that were providing
the service were covered in the study.
All the covered five public health facilities were located in Dire Dawa town except one which
was 9 KMs away. The only hospital in Dire Dawa, Dil Chora, is the oldest of all facilities that
has served for more than 50 years while the rest are relatively younger. Unlike the health centers,
which were mostly serving Dire Dawa’s population, Dil Chora referral hospital provided its
services to patients from the neighboring regions (Afar, Somali, Oromia, Harari) and sometimes
from neighboring countries (Somalia and Djibouti).
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4.2. Study design
The study employed both qualitative and cross-sectional quantitative designs and was conducted
from March to June, 2009. In-depth interviews were conducted with facility managers to gather
qualitative data with regards to service availability and efficiency while additional data was
collected by observation and document review. Data on adherence rate (outcome variable) and
its possible determinants (independent variables) was collected through patient exit-interview at
one point in time.
4.3. Study population
The study population consisted of PLHIV, who were enrolled for chronic HIV care and already
on IPT by the time of visit, heads of facilities and service providers. For the patient exit
interview, the participant IPT clients were only those who were at least 18 years old by the time
of data collection. For the prevalence study, patient records of those patients who were enrolled
for HIV chronic care in the previos five months (November 14, 2008 to April 12, 2009) were
reviewed. This period was selected because of the fact that IPT service was restarted only
starting November 14, 2009 when the drug was made available after over one year of supply
interruption. Those patients with incomplete information in their records, children < 14 years of
age for whom TB screening is difficult, and pregnant women for whom IPT is not recommended
were excluded from the prevalence study.
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4.4. Variables
4.4.1. Dependent variable
The dependent variable was level of adherence to IPT.
4.4.2. Independent variables
The independent variables were age, sex, level of education, patient status and patient care
indicators (travel time, waiting time, cost of transport and proper labeling of drugs).
4.5. Sample size determination and sampling procedure
Applying a finite population correction formula, with 95%CI, 5% margin of error, P=0.5, and
N=625 resulted in a sample size of 238; adding 10% additions for non-response made the total
sample size 261 (where P refers to the expected adherence level and N is the total number of
patients who were on IPT). The value of P is taken as 0.5 (50%) because there is no documented
estimate of adherence rate to IPT in Dire Dawa. The calculated sample size and the actual
number of data analyzed are presented in Table 1 disaggregated by health facility.
Table 1 Sample size determination for patient exit interview
Name of health
facility
Total #
PLHIV on
IPT
%
PLHIV
on IPT
Sample size/Weighted
sample
Actual # of data
analyzed
Dil Chora hospital 384 61.4 160 144
Sbian HC 108 17.2 45 41
Dire Dawa HC 77 12.3 32 31
Melka Jebdu HC 8 1.3 3 3
Legehare HC 48 7.7 20 19
Total 625 100 260 238
For the exit interview, since patients come to facilities only on a monthly basis, it would take a
very long time to interview the required number of patients if random sampling is applied.
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Accordingly, to accommodate for the time limitation, consecutive patients who were HIV
positive and prescribed with INH were invited to participate in the completion of the
questionnaire that was done by trained health professionals (Figure 2).
Figure 2 Sampling procedure for patient exit interview
A total of 251 interviews were conducted of which 238 (94.82%) were selected for analysis after
filtering those with inconsistent and missing information; this was at an average of 48 interviews
per facility. The numbers of interviews vary greatly among the facilities with the minimum of 3
and the maximum of 144.
Enrolled PLHIV in
facilities
PLHIV on ART PLHIV on pre-ART
Eligible for IPT Not eligible for IPT Not eligible for IPT Eligible for IPT
PLHIV not on IPT
PLHIV on IPT
PLHIV not on IPT
PLHIV on IPT
Selected study
participants for
patient exit
interview
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To gather information with regards to service provision and facility organization, in-depth
interview and facility observation techniques were employed in four of the five facilities
including one hospital and three health centers (Table 2). In depth interview was conducted to
collect information from facility managers, while additional information were gathered from
professionals including staff of the ART clinic, TB clinic, pharmacy, and laboratory. For specific
quantitative information, relevant secondary data were also consulted including patient records,
laboratory ledgers and pharmacy records.
Table 2 Names of visited health facilities and type of data collected
Names of
facilities
Type of facility* Type of data collected
Facility Observation
(Y/N)
In-depth
interview (Y/N)
Patient exit
interview (Y/N)
Dil Chora Referral hospital Y Y Y
Sabian Type A health center Y Y Y
Legehare Type A health center Y Y Y
Melka
Jebdu
Type A health center Y Y Y
Dire Dawa Type A health center N** N Y
* All are public health facilities
** Data on IPT service was collected through document review
To determine the prevalence of IPT, data was collected from records of patients who were
enrolled during the past 5 months from the initial day of data collection (November 14, 2008 to
April 12, 2009). The period was chosen for the reason that INH was continuously available only
from November, 2008 onwards. If data was collected for the duration including the time that the
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drug was unavailable, the results would be biased since unavailability of the drug affect the
prescription pattern (initiation of IPT).
4.6. Data collection Period
The pre-test, training and data collection were conducted from April 8 to May 22, 2009. During
the first two weeks, data was collected from health service providers and different secondary
data sources. Patient exit interviews were undertaken in six weeks time; originally, it was
planned to finalize this activity in three weeks time assuming that sufficient number of
participants would turn out.
4.7. Data collection instruments
The study employed three types of data collection instruments, which are attached as Annex II.
All the data collection tools were amended from the INRUD-IAA project that is developed by
Management Sciences for Health (MSH), Karolinska Institute, Harvard University, and the
World Health Organization (WHO) in collaboration with INRUD groups in Ethiopia, Kenya,
Rwanda, Tanzania, and Uganda (23).
The first tool was a semi-structured questionnaire (Tool 1), which was used for in-depth
interview with the heads of the health facilities with issues focusing on organizational capacity,
service provision, integration of services and IPT implementation. This activity was performed to
understand the general situation of the service and to gather realistic recommendations as seen
from managerial level.
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The second instrument was a checklist (Tool 2), which was used to collect data on facility
organization, service provision and prevalence of IPT among eligible individuals. Data was
collected from different units of the health facility primarily through observation and document
review. Brief discussions were also held with relevant staff whenever required.
The patient exit interview instrument (Tool 3) is a structured questionnaire, which was used to
collect data on adherence from IPT clients. This tool was used to collect information on socio-
demographic characteristics of patients and rate of adherence to IPT. The reasons for non-
adherence and other relevant information were also gathered from the study participants.
Before the actual data collection, the instruments were field-tested in Dil Chora hospital of Dire
Dawa city administration by the principal investigator. The field test was planned to assess the
logical flow of the questions, understanding by respondents, missed points and other relevant
issues. Based on the findings of the pre-test, the instruments were finalized and duplicated for
use. Dil Chora hospital was also included in the actual study but this time data was collected
from different study participants by trained health professionals.
4.8. Data collectors
The data collectors were health professionals, composed of nurses and pharmacy professionals,
who were working in health facilities of Dire Dawa city administration. These professionals were
selected based on the fact that they were familiar to the health services and that they could stay
there as long as it took to collect data from patients; this was taking the limited time and cost that
was available for the study. Moreover, since they were working in the study facilities, it was easy
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to get information on those patients who were on IPT among which study subjects were selected,
which would have otherwise been difficult had other data collectors were recruited. Prior to data
collection, they received a two days training on how to complete the tools that included practical
data collection simulation sessions. The principal investigator and one additional supervisor
supervised the data collection process and provided on-site advice as required. The additional
supervisor was a senior health professional from the Dire Dawa health bureau, who was working
as a focal person for TB/HIV activities in Dire Dawa city administration. All in-depth interviews
were conducted by the principal investigator.
4.9. Data entry and analysis
Data collected by the instruments were edited and checked for missing items and consistency in
the field. Prior to data entry data were edited and post-coded for computerization. One employed
data clerk and the principal investigator entered the data in to the computer and the data were
cross-checked for error. SPSS version 16.0 was used for analysis. Univariate analysis was
performed and descriptive statistics were generated for the overall socio-demographic
characteristics of the population and patient care indicators. Binary logistic regression tests were
conducted to assess the association of independent and dependent variables at 0.05 level of
significance. For analysis purpose age, transport cost, travel time and waiting times were
categorized in to groups.
Qualitative data regarding facility organization and service provision were analyzed thematically
and summaries of the findings were documented. Similarities and differences among the health
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facilities were critically weighed and presented. In this report, qualitative and quantitative data
are presented in such a way they complement each other.
4.10. Ethical consideration
Approval of ethical clearance was secured from Ethical Clearance Committee of the School of
Public Health, University of Gondar. In response to a written letter of request for cooperation
from the ACIPH management, a written permission was secured from Dire Dawa City
Administration Health Bureau.
Data collectors were trained on how to handle sensitive and emotional issues and on the
importance of keeping confidentiality. A designed consent form (Annex I) was used to obtain
study subjects’ agreement to participate in the study, following an explanation about the purpose
of the study and what is expected of them. Names and any other sensitive personal information
of individual study subjects were not recorded during data collection and assurance of
confidentiality was provided prior to interview. Furthermore, data collectors who were not
directly involved in ART and IPT service provision were chosen for this study. Only authorized
people had access to raw data collected from the field. The final study report shall be
disseminated to Dire Dawa City Administration health bureau, all the visited health facilities,
Federal Ministry of Health and MSH-Ethiopia office.
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4.11. Operational definitions
The following words/terms were used in this study with their corresponding operational
definitions.
Prevalence of IPT: The prevalence of IPT is the proportion of those eligible PLHIV who
received the preventive therapy. It is determined by dividing the number of individuals who
received IPT by the total number of individuals enrolled for HIV care and who were eligible for
the treatment in a specified period of time.
Complete adherence: An individual is said to completely adhere to IPT if s/he took all the
prescribed doses for specified period of time. Thus, complete adherence is the proportion of
individuals who reportedly took all the seven doses of INH in the past seven days.
Adherence rate: For this study, adherence rate is expressed as the proportion of those
individuals who reportedly took at least 85% of the prescribed doses of INH during the past
seven days.
Proper labeling: A drug is said to be properly labeled if the label contains at least the following
information: drug name, strength, dose and dose per day.
Patient knowledge: A patient is said to know how to take the medicine if s/he is able to tell the
name of the drug and the number of doses to take per day.
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5. Results
5.1. Results of facility observation and in-depth interviews
On average, 3 professionals work full time (week days) in the ART clinics (Facility range: 2 - 4),
with main responsibilities of providing comprehensive HIV care services. All the four ART
clinics were open for 39 hours per week (8 hours per day Monday through Thursday and 7 hours
on Fridays) while two facilities were open on Saturdays for 4 hours. The mean daily patient
loads per facility and per health care provider, at the ART clinics, were 58.86 and 4.91,
respectively. Because actually less number of patients come to facilities at the weekends the
workload was calculated only for the five working days. With the exception of one staff in
Sabian health center, all staff working in ART clinics were trained on TB/HIV collaborative
activities in general and IPT-implementation guideline in particular. Implementation Guidelines
for TB/HIV Collaborative activities in Ethiopia was available in all facilities and all staffs were
applying the proper eligibility criteria as per the guideline. TB screening and IPT monitoring tool
was universally used with 24 incomplete forms found while data was collected from patient
cards.
Pharmacies and laboratories were providing round-the-clock service throughout the year;
however, opening hours did not necessarily indicate provision of HIV and TB related services as
these services were usually provided during the formal 39 hours working hours during the five
week days. For those patients who could not come in week days, facilities implemented a special
arrangement for service provision during off-working hours and on week ends. IPT service had
been discontinued for about two years due to unavailability of INH until November, 2009, which
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was the time when the drug supply was re-instated. Since then, none of the facilities faced supply
interruption with 100% (N 4) negative response to stock out in the past 90 days. Availability of
INH 300mg and Pyridoxine by the time of visit was 100% in all facilities whereas that of
INH100mg was 75% (N 4). As part of the comprehensive HIV care service, both INH and
pyridoxine were provided free of charge (Table 3).
All facilities had functional laboratories and were staffed with qualified professionals by the time
of visit. Dil Chora hospital was serving as a referral center for the health centers regarding all
kinds of services including X-ray facility. The average number of laboratory professionals per
facility was 6 (Facility range: 3 - 15). With an average number of 3 staff (Facility range: 2 - 7),
the staffing was also good for the pharmacies.
ART service was well integrated with other services provided in the facilities. With the
exception of one, ‘intra-facility referral form’ was used in all facilities to link patients with the
relevant service point. In Melka Jebdu health center, linking clients with the next service point
in-person contributed a lot in reducing the proportion of patients who might have left the facility
without getting the service. The multi-disciplinary team (MDT) and the facility HIV committee
(FHC) provided a strong base for service integration through their weekly and monthly meetings,
respectively.
According to the head’s of the facilities, acceptance of IPT among professionals was good.
Adherence counseling was given to patients prior to IPT initiation although this study did not
assess the details of the issues addressed. Patients’ adherence was reportedly assessed during
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each repeat visit through patient-provider discussion to identify barriers and make appropriate
decisions. It was reported that peer-counselors were playing an important role in promoting
adherence to both ARV drugs and INH.
A registration book to document individual level data on IPT was observed in all sites visited,
which was found to have a varying degree of aggregation among facilities. However, compiled
reports were unavailable in all visited sites (Table 3).
Table 3 Observed vailability of services in the facilities
Observations Status and Number of
Facilities (N = 4)
Yes No
Drug available by time of visit
INH300mg
INH100mg
Vitamin B6
4
3
4
0
1
0
Stock out of drugs in previous 90 days 0 4
Availability of counseling room
ART clinic
Pharmacy
4
4
0
0
Functional laboratory 4 0
AFB microscopy done? 4 0
CXR available 1 3
Availability of reagents by time of visit
Acid-alcohol
Stain
4
4
0
0
Stock out of reagents in previous 90 days 0 4
Guideline available* 4 0
Data on IPT available** 4 0
* Implementation guidelines for TB/HIV collaboration activities in Ethiopia
** Only individual level, but no aggregated, data on IPT.
The main challenges reported by the health facility managers were high professional turn over
and inadequacy of refresher trainings. Two of the health facilities also reported a space problem.
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5.2. Results of prevalence assessment
Record review showed that the aggregated prevalence for Dire Dawa city administration public
health facilities was 37.29% (N 480) with the minimum of 20.29% for Sabian health center and a
maximum of 83.33% at Melka Jebdu (Table 4).
Table 4 Prevalence of IPT in Dire Dawa city administration public health facilities
# of PLHIV
eligible for IPT
# of PLHIV for
whom IPT was
initiated
% PLHIV for whom
IPT was initiated (IPT
Prevalence)
Legehare HC 47 15 31.91
Dil Chora Hospital 313 128 40.89
Sabian HC 69 14 20.29
Melka Jebdu HC 6 5 83.33
Dire Dawa HC 45 17 37.78
Aggregated for Dire
Dawa 480 179 37.29
Na
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5.3. Results of adherence assessment
The mean age of participants was 34.63 (SD 9.12) with a median age of 34 years, and 157 of
them (65.97%) were females (Facility range: 43.37% - 100%). The majority of them (N 238,
67.6%) were on anti-retroviral therapy (ART), and 222 (N 238, 93.3%) of the participants were
able to do their normal activities (Table 5).
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Table 5 Summary of socio-demographic characteristics of study participants
Name of facility
#
interviews
Average
Age
%
Female
% on
ART
% able to do
normal activity
Dil chora hospital 144 34.55 69.44 75.69 93.06
Sabian health center 41 34.59 73.17 34.15 100.00
Dire Dawa health center 31 34.42 48.39 80.65 90.32
Melka Jebdu health cent. 3 32.00 100.00 100.00 66.67
Legehare health center 19 36.16 47.37 52.63 89.47
Aggregated Mean for
Dire Dawa 48 34.63 65.97 67.65 93.28
Maximum among facilities 144 36.20 100.00 100.00 100.00
Minimum among facilities 3 32.00 47.40 34.15 66.67
The average cost of transport was 3.02 birr (SD 13.72) with more than 89 percent of respondents
pay 2 birr or less. The average times patients spent on travel and in the facility were 29 and 25
minutes, respectively, making the total time that the patient requires to get medical service less
than one hour. Proper drug labeling was 73.46 percent (N 161) for the ARV drugs and 66.37
percent (N 238) for INH, which was poor when compared to the ideal 100 percent. Despite this,
however, patient’s knowledge with regards to drug dosage was very good with 160 (N 161,
99.8%) and 238 (N 238, 100%) of the participants reported to know how to take ARV drugs and
INH, respectively (Table 6).
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Table 6 Summary of patient care indicators
Name of
facility
#
interview
s
% patients
INH
dispensed
% ARV
drugs well
labelled
% INH
well
labelled
% know
dose of
ARVs
% know
dose of
INH
Average
cost to
clinic(birr)
Average time
to facility
(minutes
Average time  in
facility(minutes)
Dil chora
hospital 144 99.31 73.64 59.03 99.08 100.00 3.97 39.95 44.98
Sabian health
center 41 97.56 92.86 100.00 100.00 100.00 1.59 26.34 27.68
Dire Dawa
health center 31 100.00 60.00 58.06 100.00 100.00 1.74 38.39 25.65
Melka Jebdu
health center 3 100.00 0.00 0.00 100.00 100.00 0.00 13.33 4.00
Legehare health
center 19 100.00 100.00 73.68 100.00 100.00 1.47 25.26 21.47
Mean 48 99.16 73.46 66.39 99.38 100.00 3.02 35.89 37.09
Maximum 144 100.00 100.00 100.00 100.00 100.00 3.97 39.95 44.98
Minimum 3 97.56 0.00 0.00 99.08 100.00 0.00 13.33 4.00
Of the 238 participants, 52 (21.85%) missed one or more doses of INH in the past seven days.
The aggregated self-reported complete adherence was 78.15 percent while self-reported
adherence rate was 84.87 percent (N 238) (Table 7).
Table 7 Adherence rate
Dil Chora
hospital
Sbian
HC
Dire
Dawa HC
Melka
Jebdu HC
Legehare
HC
Aggregated
(Mean)
Complete
adherence
78.47 80.49 74.19 100 73.68 78.15
Adherence
rate
84.03 82.93 87.10 100 89.47 84.86
5.4. Results on assessment of factors of adherence
Ten of the non-adherent (19.23%) missed all the seven doses with 70 percent of them reported
the reason as being away from their home (Table 8 and 9).
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Table 8 Frequency of INH doses missed in the previous seven days
N
um
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Name of health facility
TotalDil chora
hospital
Sabian
health center
Dire Dawa
health center
Melka Jebdu
health center
Legehare
health center
0 Count 113 33 23 3 14 186
% within Number of INH doses missed 60.8% 17.7% 12.4% 1.6% 7.5% 100.0%
% with in facility 78.5% 80.5% 74.2% 100.0% 73.7% 78.2%
1 Count 8 1 4 0 3 16
% within Number of INH doses missed 50.0% 6.2% 25.0% .0% 18.8% 100.0%
% with in facility 5.6% 2.4% 12.9% .0% 15.8% 6.7%
2 Count 2 3 1 0 1 7
% within Number of INH doses missed 28.6% 42.9% 14.3% .0% 14.3% 100.0%
% with in facility 1.4% 7.3% 3.2% .0% 5.3% 2.9%
3 Count 6 1 0 0 1 8
% within Number of INH doses missed 75.0% 12.5% .0% .0% 12.5% 100.0%
% with in facility 4.2% 2.4% .0% .0% 5.3% 3.4%
4 Count 6 0 1 0 0 7
% within Number of INH doses missed 85.7% .0% 14.3% .0% .0% 100.0%
% with in facility 4.2% .0% 3.2% .0% .0% 2.9%
5 Count 2 0 1 0 0 3
% within Number of INH doses missed 66.7% .0% 33.3% .0% .0% 100.0%
% with in facility 1.4% .0% 3.2% .0% .0% 1.3%
6 Count 0 1 0 0 0 1
% within Number of INH doses missed .0% 100.0% .0% .0% .0% 100.0%
% with in facility .0% 2.4% .0% .0% .0% .4%
7 Count 7 2 1 0 0 10
% within Number of INH doses missed 70.0% 20.0% 10.0% .0% .0% 100.0%
% with in facility 4.9% 4.9% 3.2% .0% .0% 4.2%
Total Count 144 41 31 3 19 238
% within Number of INH doses missed 60.5% 17.2% 13.0% 1.3% 8.0% 100.0%
% with in facility 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
The most common reasons forwarded by participants for missing INH doses were being away
from residential area, stock out at facilities, forgetfulness and running out of pills. These factors
contributed about 75% (N 52) of the reported reasons for non-adherence (Table 8).
Table 9 Frequencies of reasons forwarded by patients for missing INH doses
Reasons for missing INH dose/s Respondents
Number %
Patient away from home 16 30.77
Forgot to take 11 21.15
Patient run out of pills 7 13.46
Drug out of stock at facility 5 9.62
Toxicity/side effect 3 5.76
Too ill to take pills 2 3.85
Fear of stigma/discrimination 2 3.85
Fasting 2 3.85
Drug shared with others 1 1.92
Too many pills/pill burden 1 1.92
Long waiting time 1 1.92
Missed appointment 1 1.92
Total 52 100
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Socio-demographic variables and all the patient care indicators were not significantly associated
with adherence. However, all participants with high level educational level (diploma holders and
above) were 100 percent adherent to both ART and IPT. Of the females, 136 (N 157, 86%) were
adherent to IPT compared to 66 of the males (N 81, 81.48%) showing that females were more
adherent than males by almost 50 percent. The Adherence rate was also better for those on ART
as compared to those who were on pre-ART by more than 60 percent. However, when the other
factors were adjusted, the odds of adherence considerably decline for both females and those on
ART as compared to their corresponding crude values (Table 9).
Table 10 Association of factors with adherence
Factors Adherent (N 238) Crude OR (95% CI) Adjusted OR (95% CI)
Yes No
Sex
Male
Female
66
136
15
21
1
1.47 (0.71-3.03)
1
0.72 (0.31-1.66)
Patient status
Pre-ART
On ART
62
140
15
21
1
1.61 (0.78-3.34)
1
0.49 (0.22-1.09)
Age
18 – 24
25 – 34
35 and above
22
78
102
5
16
15
1
0.90 (0.30-2.74)
0.65 (0.21-1.97)
1
0.77 (0.24-2.55)
0.51 (0.15-1.72)
Level of education
Illiterate
Primary education
Secondary education
63
95
32
8
24
4
1
1.99 (0.84-4.71)
0.98 (0.28-3.52)
1
2.20 (0.87-5.54)
0.87 (0.23-3.30)
Cost of transport in birr (home to clinic)
0 – 2
3 – 10
180
17
33
3
1
0.96 (0.27-3.47)
1
0.62 (0.10-3.95)
Travel time in minutes (home to clinic)
0 – 30
31 – 60
61 – 120
136
58
5
23
10
3
1
1.02 (0.46-2.28)
3.55 (0.79-15.87)
1
1.05 (0.41-2.65)
6.21 (0.73-52.69)
Waiting time in minutes (in clinic)
0 – 30
31 – 60
61 – 120
135
43
19
21
10
5
1
1.50 (0.65-3.42)
1.69 (0.57-5.02)
1
2.24 (0.88-5.72)
2.98 (0.87-10.21)
30
The calculated crude and adjusted odds ratio were zero for those patients with high level of
education (diploma holders and above), who paid more that 10 birr for transport, who spent more
than 120 minutes traveling and those who spent more than 120 minutes in the facility.
6. Discussion
6.1. Health facilities’ organizational capacity
In general terms, the study found out that the health facilities were organized in such a way that
they were able to provide quality health services. The exceptional strength observed in all
facilities was the strong service integration through intra-facility referral system and the strong
coordinated leadership provided by the multi-disciplinary team (MDT) and facility HIV
committee (FHC). Specific to services provided at the ART clinics, professional staff availability
and mix was good with at least one medical doctor/health officer assigned full time supported by
trained nurse/s. However, the need to recruit and/or train more staff should be planned to
mitigate the high professional turn over that prevails currently.
The calculated work load for the facilities was 4.91 patients/professional/day, which was lower
than a documented 16 patients/professional/day reported by a national study conducted in
Ethiopia (23).  Though results show a relatively lower work load in Dire Dawa, the huge
difference among facilities (Facility range: 0.98 - 58.86) should not be overlooked. For instance,
with 58.86 patients daily visit per professional at Dil Chora hospital, one would not expect an
adequate consultation time for quality service provision.
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Working environment was also satisfactory with a chance for relevant trainings, availability of
isolated counseling rooms, appropriate guidelines, drugs, laboratory services and a team-oriented
attitude. Informal data collected from patients and information from heads of facilities suggested
that the patient-provider information was very good. The role of peer counselors in tracing
defaulters and in promoting adherence to treatment was another plus to the efforts of the
facilities.
Some of the weaknesses observed were poor documentation with regards to IPT service and
absence of or incomplete ‘TB screening and IPT monitoring tool’ for some cases. The patient
level data on IPT, registered in a separate log book, was not compiled in such a way that
simplified information extraction for easy understanding and monitoring. The newly
implemented HMIS, which was designed to create a harmonized filing system, was also another
challenge that facilities faced, especially in tracing records of patients who were enrolled in HIV
chronic care program; totally, 20 patient cards were not found in the five facilities.
6.2. Prevalence of IPT
Despite the observed enabling factors, however, the prevalence of IPT was very low (37.29%).
This figure is of course by much higher than the global 0.06% IPT prevalence reported by WHO
in 2005 (5). However, it was in contrast with the information from facility managers who, with
no exception, reported that IPT was provided to the majority, if not all, of the eligible. This
perceived high coverage by the facility managers might have emerged because none of the
facilities had a compiled data (report) on IPT service.
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Though the study did not try to identify the reasons in detail, one of the possible reasons for this
low level of IPT coverage might be the weak facility level supervision and mentoring. This
argument might be supported by the observed immediate corrective action that the staff of
Legehare health center took by starting to put almost all eligible individuals on IPT following the
first day of data collection at the facility. Another possible reason is the difficulty in ruling out
active TB by the existing diagnostic facility and existing staff capacity. However, the above
mentioned reasons might have contributed to the reported low prevalence but should not be taken
as the only reasons by any means.
6.3. Level of adherence
The adherence rate determined by this study (84.87%) was higher than results of other studies
done in South Africa (72%) and Thailand (67.5%) (7, 9). However, it was lower than reported
88.2 percent adherence by a study conducted in America (8) (Table 8). A number of factors
might explain the difference: the difference in the assessment methodologies, the cut off points,
the study setting, the time of the study and others.
The study in America (8), which employed a number of different methods, indicated that self-
report overestimates adherence as compared to more objective methods of evaluation such as
urine test and electronic lead monitor. The South African study, for instance, determined
adherence through a more objective method (urine test), which was able to detect INH
metabolites in the urine. In Thailand pill count was used to measure adherence. In general, the
non-adherence rate in Dire Dawa (15.13%) was with in the range of 11.8 to 37 percent rates that
were reported by other studies (6 - 9).
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6.4. Factors of adherence
Of the three groups of possible factors that would affect adherence (Figure 1), the results showed
that the contributions of health service and community level factors to non-adherence were
minimal. Long waiting time (health service factor) and fear of stigma/discrimination (community
level factor) were given as reason for not taking INH doses by only 1 (1.92%) and 2 (3.85%)
patients, respectively. The stock out at facilities was reported by five respondents (N 52, 9.62%)
was not supported by the findings of the facility observations, which informed that the drugs
were continuously available since November, 2008.
The most frequently mentioned reasons were traveling away from residential area, forgetfulness
and running out of pills, which are individual factors and have a lot to do with attitude and self
discipline. This was in contrast with reported good pre and post treatment adherence counseling
by facility managers because the mentioned reasons might possibly be explained by lack of clear
understanding of treatment and self–discipline. The difference between the adherence rates to
IPT (84.87%) and to that of ARV drugs (90.69) could also be due to patients’ varying perception
about the risks associated with missing the two groups of drugs. While further investigations are
required for better understanding of the underlying causes, these factors are indications that
inform the need for reviewing the adherence counseling strategies and take appropriate actions
for the future.
Though there was no statistically significant association between the level of education and
adherence, all participants with higher education (diploma holders and above) were 100 percent
adherent to both ART and IPT. The study did not determine if this difference in adherence arose
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from relatively better understanding among the educated or whether education affected standard
of living, which in turn promoted adherence among the better offs. Though this needs further
investigation, one can still consider the probability of designing a different approach of
counseling that addresses specific requirements of different categories of the community, and if
possible that of individuals.
Demographic and other factors such as travel time, time in facility and transportation cost, were
not found to be significantly associated with adherence. Though not significant, the observed
better adherence of females (OR 1.47) was also reported by a study in Thailand (9) while another
study in America did not find a significant effect of sex on adherence (8). One study (9) suggests
that visiting patients improves adherence, and if so, facilities should design and implement a
strategy to work very closely and collaboratively with the existing peer counselors, who are
believed to access clients at a relative ease.
Finally, this study involved professionals who were responsible for implementation of IPT and
improve adherence one way or the other. The fact that all the data collectors were health
professionals who were working in the assessed facilities and that health facility managers were
part of the study contributed a lot in helping them understand the reality with regards to IPT
service and adherence. It is the author’s firm belief that this would encourage facilities to
maximize their effort and achieve better results in the future as exemplified by the action taken
by Legehare health center.
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7. Conclusions
Health facilities were well positioned with adequate capacity to provide IPT services for those
who seek the treatment. Health facility managers reported satisfactory service coverage and
commendable achievements in adherence. However, there was a huge gap between the facility
managers’ perception and the actual results of the study; this was observed regarding both IPT
service coverage and adherence, which were low.
Patient related factors were the major reasons for missing doses among the non-adherent
constituting more than 65 percent of all causes. Health facility and community level factors were
not among the common reasons forwarded for non-adherence. None of the socio-demographic
variables, patient status and patient care indicators was found to be significantly associated with
level of adherence.
In conclusion, the findings clearly show that increasing IPT coverage and improving adherence
require much more than quality guidelines, adequate organizational capacity and availing drugs.
As indicated in the national TB/HIV implementation guidelines, the study found out that attitude
and follow-up are still the main challenges for better service utilization.
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8. Recommendations
This study indicated the need to design and implement effective strategies to increase IPT service
coverage and improve adherence. The following actions are recommended to be considered by
relevant parties:
 Examine facility specific barriers to IPT initiation and take appropriate corrective actions;
 Design and implement a strategy for periodic review of IPT service provision and
adherence; utilizing the existing functional structures (MDT, FHC) whenever feasible;
 Improve patient records’ filing system; design and implement a mechanism that would
enable to proper documentation and retrieval of IPT service related data at facility and
health bureau level;
 Strengthen the existing adherence-counseling system to guarantee high adherence rate in
such a way that addresses the reasons for non-adherence that are identified by this study;
9. Strengths of the study
One of the strengths of the study was that it involved facility managers and health professionals
working in the targeted facilities, which contributed a lot for the quality of the data. It also
helped the facilities’ staff to get first hand information about the implementation status of IPT in
their respective facilities. On the other hand, this study was among the few, if any, which
documented current situation with regards to IPT service provision in Ethiopia.
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10.Limitations of the study
One of the limitations of this study was that it did not include the private sector in Dire Dawa
that makes generalization difficult. The other limitation was that data on adherence was collected
by self report and there is a probability for recall and social desirability biases. One other
possible limitation was that the status of those individuals whose patient records were not
retrieved and those for whom TB screening form was not completed was not known, which
might have affected the results.
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12.Appendix
Appendix I: Consent form
Consent Form
This study is for partial fulfillment of a post-graduate program jointly provided by Addis
Continental Institute of Public Health and University of Gondar. The objective is to determine
the level of use of IPT and the rate of adherence among users in Dire Dawa. It will also try to
identify the possible determinants of adherence to IPT. Identifying these issues would help to
design and implement an intervention to expand the service and improve adherence.
In this study we will be collecting data from service providers and patients who are taking INH
for preventive therapy.
Since you are taking INH, we would like to ask you some questions. The information you will be
giving us will be used only for study purposes and your names and specific addresses are not
required. The information generated will be disclosed in totality and all your personal
information will be confidentially treated.
To fill this questionnaire it will take from 10 to 15 minutes. You have all the right to refuse to
answer to any of the questions and to withdraw at any time.
If you would like to participate, will you sign here please?
Principal investigator: ____________________ Participant: ____________________
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Appendix II: የተሳትፎ ስምምነት ማረጋገጫ
ይህ ጥናት በአዲስ ኮንቲነንታል ኢንስቲቲዩት ኦፍ ፐፕሊክ ¤ልዝ እና በጎንደር ዩኒቨርሲቲ
በጋራ ለሚሰጥ የድህረ-ምረቃ ስልጠና ማሟያ የሚደረግ ነው፡፡ የጥናቱ አላማም በአሁኑ
ወቅት የቲቢ መከላከያ መድሃኒት በመጠቀም ላይ የሚገኙ ሰዎችን ብዛት ለማወቅና
የአጠቃቀማቸውን ሁኔታ ለመዳሰስ ነው፡፡ በተጨማሪም፣ መድሃኒቱን በአግባቡ ለመጠቀም
የሚያግዙ መረጃዎችም ይሰበሰባሉ፡፡ የጥናቱ ውጤትም፣ የተጠቃሚዎችን ቁጥር ለማሳደግና
አጠቃቀሙንም ለማሻሻል የሚያስችሉ ስልቶችን ለመንደፍና ለመተግበር ያግዛል፡፡
ለዚህ ጥናት ከጤና ባለሙያዎችና የቲቢ መከላከያ መድሃኒቱን በመውሰድ ላይ ካሉ
ተጠቃሚዎች መረጃ ይሰበሰባል፡፡ እርስዎም የዚህ መድሃኒት ተጠቃሚ በመሆንዎ ጥቂት
ጥያቅዎች ልንጠይቅዎ እንፈልጋለን፡፡ የሚስጡን መረጃ ለዚህ ጥናት ብቻ የሚውል ሲሆን፣
ስምዎትና የሚኖሩበት አድራ-ዎትን አንመዘግብም፡፡ የጥናቱም ዉጤት በአጠቃላይ
የሚገለጽ ሲሆን ማንነትዎትን የሚያሳውቅ መረጃ በድብቅ የሚያዝ ይሆናል፡፡
ይህንን መጠይቅ ለመሙላት ከአስር እስከ አስራ አምስት ደቂቃ ይፈጃል፡፡ መመለስ
የማይፈልጉትን ማንኛውንም ጥያቄ ያለመመለስና በፈለጉት ወቅት ቃለ-ምልልሱን የማቆም
መብት አለዎት፡፡
መረጃ ሊሰጡን ፈቃደኛ ከሆኑ እባክዎ እዚህ ጋር ይፈርሙ፣
የጥናቱ መሪ፣ --------------------- የጥናቱ ተሳታፊ፣ -----------------------
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Appendix II: Data Collection instruments
Tool 1: In-depth Interview Guide with the Head of the Facility
Name of facility: ___________________________
Name of the respondent: ________________________
Name of the interviewer: ________________________
Date: ___________________________
Prior to the interview, relevant official documents should be presented including the support
letter from ACIPH/UoG and the permission from the Dire Dawa city administration health
bureau. The principal investigator should describe to the respondent about the purpose of the
study, the duration, the activities to be undertaken and all other relevant information; it is only
possible to proceed with the data collection after securing permission from the head. Most
importantly, the investigator should inform the respondent about the de-briefing on the study
findings and secure a suitable date and place accordingly.
Expected interview period: 45-60 minutes
Interview with the head of the facility
1. Organization: I would like for us to discuss the general set-up of your organization. Are
there any problems? Do you have suggestions how to resolve problems and how to,
maintain/improve performance?
2. Staff: Now let’s discuss the staffing situation in your ART clinic. Probes: Are there enough
number of persons? How is the mix between professions? How do you see the acceptance of
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IPT by the staff? Are there any problems? Do you have suggestions how to resolve the
problems? How to maintain good performance? What kind of training activities?
3. IPT service: What do you think about the coverage of IPT in your facility? Do you think the
guidelines are well communicated to your staff? How/why? What are the major challenges
with regards to initiating IPT? What do you think shall be done?
4. Supply of drugs: What is your INH supply situation? Probes: Do you ever get stock outs?
What is the reason? How do you solve it? Are there barriers to make these drugs available?
What do you suggest shall be done?
5. Patients: How do patients perceive services here? Probes: Are they satisfied with opening
hours? With staff? With laboratory services? Are there complaints about access? About
number of days for each drug delivery? What can be done to improve adherence?
6. Lab resources: What TB investigations are performed at the lab? Do you always have
reagents and other necessary things? Well-trained staff? Any other problems?
7. Integration: Do you offer the following services at your facility? HCT, ANC, PMTCT, TB,
or others? If “Yes” How does the integration function? Strengths and weaknesses?
8. General: What are the strongest features of your facility? What are the most important
barriers to better performance? Do you see any problems other than what we have discussed?
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Tool 2: Checklist for Facility Observations
1. Organization
Is the ART clinic integrated with any of the following?
 HCT Yes    __________ No    __________
 ANC/ PMTCT Yes    __________ No    __________
 TB clinic Yes    __________ No    __________
 Other Yes    __________ No    __________
2. Working Hours
Days # of Hours ART
clinic
# of Hours
Laboratory
# of Hours Pharmacy
Monday
Tuesday
Wednesday
Thursday
Friday
Saturday
Sunday
Total hours/Week
3. Staff
3.1. Is there a TB/HIV focal person in the facility?   Yes    ______  No ________
3.2. How many staff are working in ART clinic, laboratory and pharmacy in a normal day?
Unit/Department # of professional
ART clinic
Laboratory
Pharmacy
Total
4. Supply and dispensing of drugs
4.1. How many staff in the pharmacy by the day of visit?   _________
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Could I see your medical store and stock records for INH and Pyridoxine? Fill in the
following table.
No. Item Present by time
of visit (Y/N)
Stock out in the last 3
months (90 days) (Y/N)
1 Isoniazid 300 mg tablet
2 Isoniazid 100 mg tablet
3 Pyridoxine tablet
Total
4.2. Average time to dispense?  _________ (Need to observe 10 dispensing episodes and get
average time)
5. Patients
5.1. How many patients are visiting the ART clinic? _________ (Patient registration for
the day)
5.2. How many patients are visiting the pharmacy (ART)?  _________ (Dispensing
registration for the day)
5.3. Private space for counseling in ART clinic? Yes    ______  No    ________
5.4. Private space for counseling in ART pharmacy? Yes    ______  No    ________
6. Laboratory resources
6.1. Is it functional? (not at all, partially, fully) _______________________________
6.2. Do you have TB microscopy manual?
Yes: ___ No: ___
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Laboratory workload:
Description # in the past one year
# of (new) TB suspects examined
# of follow-up patients examined
Total
Note: Specify the period for the data. ________________
Fill the following table:
No. Item Present by time
of visit (Y/N)
Stock out in the last 3
months (90 days) (Y/N)
1 Acid
2 Alcohols
3 Stains
Total
7. IPT service data
7.1. Do you have the national ‘implementation guidelines for TB/HIV collaborative activities
in Ethiopia’ 2008 edition? (Check for presence)
Yes: ___ No: ___
7.2. Do you have written/documented criteria to determine eligibility for IPT?
Yes: ___ No: ___
7.3. Do you have documented data on the number of people who are on IPT?
Yes: ___ No: ___
Can I see it please?
Note: Write the name of the register/document used for this purpose.
_______________________
Fill in the following table:
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# of PLHIV enrolled
in the past 12 months
# of PLHIV eligible
for IPT
# of PLHIV for whom
IPT was initiated
# of PLHIV who
received INH
Note: If there is no documented report, go through patient records for those PLHIV who are
enrolled only during the past one year.
8. General
Overall impression of the facility
_____________________________________________________________________
_____________________________________________________________________
Tool 3: Patient Exit Interview Tool
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Na me of fa cility:  ___ ___ __ ____ ___ __ _______ ________ Da te:_________ ___ ____ ___ _
Interview er: _ ___ ____ __ ___ ____ ___ ______ ___ _______
A B C D E F G H I J K L M N O
Pt #
Age
(Yr)
Gender
(M/F)
Client
S tatu s
(P/A)
Leve l of
Ed uca tio n
(1 to 5 )
Normal
activity
(Y /N )
Cost
home to
clinic
(ETB)
Time
Ho me to
c linic (in
min s)
Time  in
Cl inic
today ( in
m ins)
Month s
on  ART
M onth s
on IPT
AR V
regime n
dispense d
(Y/N )
INH
dispensed
(Y/N)
Pyr idox ine
dispe nsed
(Y/N)
ARV drugs
w ell
labelled
(Y/N)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Ke y:
Leve l of Educatio n: 1= Illiterate, 2=primary , 3=Second ary, 4=  Diploma, 5 = first d egree and above.
Client Status: P= Pre-ART clien t, A= client on ART
Y= Yes
N= No
ET B= Eth iopian Birr
Co st: U se  both birr and cents ; i.e. 2.6  to ind icate  2 b ir r and  60 cents
Months o n ART/IPT: Write o nly co mple ted mon ths
If pyr idox in e is not p rescribed, pu t NA in columns N and Q to in dica te  Not Applicab le.
If the  answer for any o f the column s L, M  and N  is  N o (N ), pu t NA in columns O, P  and  Q a ccording ly.
Patie nt exit interview
T ool 3:  P atient Exit Interview In stru ment
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P Q R S T U V W X
INH well
labelled
(Y/N)
Vt. B6 well
labelled
(Y/N)
pt knows
how to
take
ARVs
(Y/N)
pt knows
how to take
INH
(Y/N)
# Doses
ARVs
missed in
last 7 days
# Doses
INH
missed in
last 7
days
Reason for
Missing
INH doses
(Code 1-
17)
If "Other" then
specify reason for
missing doses: Codes for column V
1 = Toxicity-Sde effect
2= Shared with others
3=Forgot
4= Felt Better
5= Too ill
6= Stigma/discrimination
7=Drug out of stock (HF)
8=Patient ran out of
pills or lost them
9= Do not know dose
10=Alcohol
11=Depression
12=Start other treatment
13= Fasting
14=Away from home
15 = too many pills
16= Long waiting time
17= Missed appointment
Specify for 'Others'
